Advances in Hematology

Molecular-Targeted Therapies for Hematologic Malignancies


Publishing date
15 Nov 2011
Status
Published
Submission deadline
15 May 2011

1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

2Department of Medicine, Case Western Reserve University, Cleveland, OH, USA

3Oncology Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA


Molecular-Targeted Therapies for Hematologic Malignancies

Description

Major advances in the disciplines of hematology, genetics, biochemistry, and chemistry over the past decades have empowered investigators with the background and methods required for development of customized molecular-targeted therapies. The ability to identify signaling pathways that are dysregulated to determine the associated mutations and to develop chemical drugs toward a desired correction is now a reality. Through much hard work, we now know the key drivers of some hematologic malignancies, and depending on the particular disease, we have an arsenal of agents available to act at multiple nodal points. Some enabling technologies that have been a key for these advances include small molecule screening, high throughput whole genome sequencing, mouse models for cancer, and gene and microRNA expression array analyses. In this special issue, we aim to publish articles that contribute to our understanding of molecular targets and the development of approaches for their inhibition or rationale use of existing agents or their derivatives. This can include targeting aberrantly activated drivers of leukemogenesis or key supportive pathways that are essential for maintenance and progression of hematologic disease. Molecular-targeted therapies have already been validated in chronic myelogenous leukemia and bring great promise for therapy of leukemia, lymphoma, and plasma cell dyscrasias. This special issue will be open to review articles in addition to the original research articles. The topics to be covered include, but are not limited to:

  • Approaches to understand and block abnormal myeloproliferation and the associated pathologies of the bone marrow
  • Therapies that target leukemias and lymphomas driven by oncogenes and their critical targets
  • Therapies that target the proteasome because of specific efficacy in diseases such as myeloma and further understanding of the mechanisms
  • Studies of signal transduction molecules critical for hematopoietic stem and progenitor cell survival, proliferation, and self-renewal
  • Guidelines for clinical applications and trials

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ah/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 606423
  • - Editorial

Molecular-Targeted Therapies for Hematologic Malignancies

Kevin D. Bunting | Cheng-Kui Qu | Michael H. Tomasson
  • Special Issue
  • - Volume 2012
  • - Article ID 380635
  • - Review Article

Gab Adapter Proteins as Therapeutic Targets for Hematologic Disease

Sheetal Verma | Tamisha Vaughan | Kevin D. Bunting
  • Special Issue
  • - Volume 2012
  • - Article ID 308252
  • - Review Article

Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia

Xiaoling Liu | Himalee Sabnis | ... | Cheng-Kui Qu
  • Special Issue
  • - Volume 2012
  • - Article ID 879368
  • - Review Article

Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies

Junko Okabe-Kado | Takashi Kasukabe | Yasuhiko Kaneko
  • Special Issue
  • - Volume 2012
  • - Article ID 524308
  • - Review Article

The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias

Flora Tzifi | Christina Economopoulou | ... | Andreas Scorilas
  • Special Issue
  • - Volume 2012
  • - Article ID 595060
  • - Review Article

Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia

Philipp Koehler | Patrick Schmidt | ... | Hinrich Abken
  • Special Issue
  • - Volume 2012
  • - Article ID 469592
  • - Review Article

Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy

Amir T. Fathi | Omar Abdel-Wahab
  • Special Issue
  • - Volume 2012
  • - Article ID 435342
  • - Review Article

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas

Pinelopi Argyriou | Panagiota Economopoulou | Sotirios Papageorgiou
Advances in Hematology
 Journal metrics
Acceptance rate8%
Submission to final decision77 days
Acceptance to publication25 days
CiteScore3.800
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.